"Ribavirin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
| Descriptor ID |
D012254
|
| MeSH Number(s) |
D13.570.800.790
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ribavirin".
Below are MeSH descriptors whose meaning is more specific than "Ribavirin".
This graph shows the total number of publications written about "Ribavirin" by people in this website by year, and whether "Ribavirin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2006 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ribavirin" by people in Profiles.
-
Salama H, Medhat E, Shaheen M, Zekri AN, Darwish T, Ghoneum M. Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial. Int J Immunopathol Pharmacol. 2016 Dec; 29(4):647-653.
-
Roytman M, Ramkissoon R, Wu C, Hong L, Trujillo R, Huddleston L, Poerzgen P, Seto T, Wong L, Tsai N. Examining the clinical course of genotype 1 chronic hepatitis C patients treated with the cosmos regimen: including patients with advanced liver disease and East Asian ancestry. Hepatol Int. 2016 Jul; 10(4):616-23.
-
Morales-V?squez L, Miranda-Avalo EI, Rodr?guez-Medina JR, Qui?ones-Badillo Y, Marqu?s-Lespier J, Mu?oz-Acab? J, Pastrana R, P?rez-Cardona CM, Yamamura Y, Torres EA. Demographics, clinical characteristics, IFNL3- and IFNL4- polymorphisms in a cohort of hepatitis C patients from Puerto Rico. P R Health Sci J. 2014 Dec; 33(4):177-83.
-
Rodr?guez-Torres M, Burguera J, Hallman D, Rodr?guez-Orengo J, Echeandia M. ?Hepatitis C viral kinetics in Latino patients: a comparison to African American and Caucasian patients. Ann Hepatol. 2012 Jul-Aug; 11(4):450-63.
-
Iturrino J, S?nchez CJ, Ortiz A, Romero CJ, Vel?zquez V, Costas P, Torres EA. Outcomes of an underserved Hispanic population with chronic hepatitis C treated with pegylated-interferon and ribavirin in a government-sponsored clinic. P R Health Sci J. 2011 Mar; 30(1):9-13.
-
Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC. Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment. Int J Med Sci. 2010 Jan 22; 7(1):36-42.
-
Rodr?guez-Torres M, Rodr?guez-Orengo JF, R?os-Bedoya CF, Fern?ndez-Carbia A, Gonz?lez-Lassalle E, Salgado-Mercado R, Marxuach-Cu?tara AM. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol. 2007 Jan; 38(1):32-8.
-
Mu?oz H, Arroyo J, Torres EA, De Jesus-Monge WE, Chinea B, Gonz?lez H, Aponte N, Guzm?n A, Rivera C, Rodr?guez F, Toro DH. Response to combination therapy of interferon alfa-2b plus ribavirin in Hispanics with chronic hepatitis C. P R Health Sci J. 2004 Jun; 23(2 Suppl):61-7.
-
Costas P, Ortiz A, Vel?zquez V, Torres EA. A government sponsored clinic for the evaluation and treatment of chronic hepatitis C in an underinsured population in Puerto Rico. P R Health Sci J. 2004 Jun; 23(2 Suppl):41-7.
-
Gonz?lez H, R?os ME, Torres EA, Mu?oz H, Arroyo J, Castro FJ. Folic acid supplementation does not prevent ribavirin-induced anemia. P R Health Sci J. 2003 Dec; 22(4):359-62.